Johnson & Johnson’s Janssen is ramping up its gene therapy work, forking over $100 million up front to develop MeiraGTx’s clinical-stage gene therapies for retinal diseases. Under the deal, the partners will work together on gene therapies for achromatopsia caused by mutations in either CNGB3 or CNGA3 and X-linked retinitis pigmentosa. Source: Fierce Biotech 31/1/2019